Amag Pharmaceuticals, Inc. Watch

ended 09/30/20 Q3

ended 12/31/19 FY 2019 – amended

ended 06/30/20 Q2

Late quarterly filing notification for Q2 2020

ended 03/31/20 Q1

Securities registration termination

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Camber Capital Management LP

Palo Alto Investors LP

Renaissance Technologies LLC

Scoon Davey

Phillips Anne M.

New Financial Obligation or Off-Balance Sheet Arrangement

Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Increase/Acceleration of Financial Obligation or Off-Balance Sheet Arrangement, Notice of Delisting, Failure to Satisfy Listing Rule, or Transfer of Listing, Material Modification to Rights of Security Holders, Change of Control, Change in Directors, Officers or Compensation, Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Financial Statements or Exhibits

Provides Update on Fda’s Proposal Regarding Makena®

Support Agreement

Other Events

Definitive proxy

Preliminary proxy

Additional info about upcoming vote

Additional info about upcoming vote

Revised proxy by non-management

Confidential treatment order

Confidential treatment order

Confidential treatment order

Confidential treatment order

Correspondence with the SEC